Orphan Drug Designation in Hypochondroplasia VOXZOGO also recently received orphan drug designation from the FDA for the treatment of hypochondroplasia a genetic condition caused by a mutation in the fibroblast growth factor receptor 3 FGFR3 gene and characterized by impaired bone growth